• argenx announces U.S. FDA acceptance of biologics license application for subcutaneous efgartigimod in generalized myasthenia gravis with priority review

    Tuesday November 22nd 2022

  • Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023

    Monday November 21st 2022

  • BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma

    Thursday November 17th 2022

  • Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia

    Tuesday November 15th 2022

  • Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

    Tuesday November 15th 2022

  • UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

    Monday November 14th 2022

  • Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

    Friday November 11th 2022

  • Is Belgium becoming a hub for gene therapy?

    Thursday November 10th 2022

  • Your news here?

  • The QbD Group acquires regulatory affairs and pharmacovigilance company EUDRAC Ltd to expand its services for pharmaceutical customers

    Tuesday November 8th 2022

  • New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients

    Tuesday November 8th 2022

  • BIO INX and Nanoscribe expand their partnership with the launch of HYDROBIO INX© N400, a new biocompatible high resolution bioink enabling live cell encapsulation

    Tuesday November 8th 2022

Strategic Partners